Daxor’s New BVA Technology To Be Showcased At MedAxiom CV Transforum Fall '25
Daxor (NASDAQ: DXR) will exhibit at the MedAxiom Cardiovascular Transforum Fall'25 at the JW Marriott Austin from October 16–18, 2025. The company plans to debut its next‑generation BVA diagnostic system and demonstrate how the technology addresses hospital readmissions and resource optimization for cardiovascular providers. CEO Michael Feldschuh said the launch is expected to accelerate sales momentum and support wider commercial adoption by connecting with cardiovascular innovators.
The appearance positions Daxor to showcase clinical and operational benefits to health systems and potential customers attending the conference in Austin, TX.
Daxor (NASDAQ: DXR) parteciperà al MedAxiom Cardiovascular Transforum Fall'25 al JW Marriott Austin dal 16 al 18 ottobre 2025. L'azienda prevede di presentare il suo prossimo sistema diagnostico BVA di nuova generazione e dimostrare come la tecnologia favorisca la riduzione delle riammissioni ospedaliere e l'ottimizzazione delle risorse per i fornitori di servizi cardiovascolari. Il CEO Michael Feldschuh ha detto che il lancio dovrebbe accelerare l'impennata delle vendite e sostenere una più ampia adozione commerciale collegandosi con innovatori nel campo cardiovascolare.
La partecipazione posiziona Daxor per mostrare benefici clinici e operativi a sistemi sanitari e potenziali clienti presenti alla conferenza ad Austin, TX.
Daxor (NASDAQ: DXR) participará en el MedAxiom Cardiovascular Transforum Fall'25 en el JW Marriott Austin del 16 al 18 de octubre de 2025. La empresa planea presentar su próximo sistema de diagnóstico BVA de última generación y demostrar cómo la tecnología aborda las readmisiones hospitalarias y la optimización de recursos para los proveedores de servicios cardiovasculares. El CEO Michael Feldschuh indicó que el lanzamiento se espera que acelere el impulso de ventas y apoye una adopción comercial más amplia conectándose con innovadores en cardiovascular.
La participación posiciona a Daxor para mostrar beneficios clínicos y operativos a los sistemas de salud y a posibles clientes que asisten a la conferencia en Austin, TX.
Daxor (NASDAQ: DXR)은 2025년 10월 16일부터 18일까지 JW 메리어트 오스틴에서 열리는 MedAxiom Cardiovascular Transforum Fall'25에 참가합니다. 회사는 차세대 BVA 진단 시스템을 처음으로 선보이고 이 기술이 심혈관 제공자들의 재입원 감소 및 자원 최적화에 어떻게 기여하는지 시연할 계획입니다. CEO Michael Feldschuh은 이번 출시가 판매 모멘텀을 가속화하고 심혈관 혁신가들과의 교류를 통해 더 넓은 상용 채택을 촉진할 것으로 기대한다고 말했습니다.
이 출현은 텍사스 오스틴에서 열리는 컨퍼런스에 참석하는 보건 시스템 및 잠재 고객들에게 임상적 및 운영상 이점을 보여줄 수 있는 위치를 Daxor에 부여합니다.
Daxor (NASDAQ: DXR) participera au MedAxiom Cardiovascular Transforum Fall'25 au JW Marriott Austin du 16 au 18 octobre 2025. L'entreprise prévoit de présenter son système de diagnostic BVA de nouvelle génération et de démontrer comment la technologie répond aux réadmissions hospitalières et à l'optimisation des ressources pour les prestataires cardiovasculaires. Le PDG Michael Feldschuh a déclaré que le lancement devrait accélérer l'élan des ventes et favoriser une adoption commerciale plus large en se connectant avec des innovateurs en cardiologie.
Cette présence permet à Daxor de mettre en avant les avantages cliniques et opérationnels pour les systèmes de santé et les clients potentiels présents à la conférence à Austin, TX.
Daxor (NASDAQ: DXR) wird an der MedAxiom Cardiovascular Transforum Fall'25 im JW Marriott Austin teilnehmen, vom 16. bis 18. Oktober 2025. Das Unternehmen plant, sein nächstes BVA-Diagnosesystem der nächsten Generation vorzustellen und zu demonstrieren, wie die Technologie Krankenhaus-Nein-Readmissionen und Ressourcennutzung für kardiovaskuläre Anbieter adressiert. CEO Michael Feldschuh sagte, der Start werde voraussichtlich die Verkaufsmomentum beschleunigen und eine breitere kommerzielle Einführung unterstützen, indem er sich mit Innovatoren im Bereich der Kardiologie vernetze.
Der Auftritt positioniert Daxor, klinische und operative Vorteile für Gesundheitssysteme und potenzielle Kunden, die an der Konferenz in Austin, TX teilnehmen, zu demonstrieren.
Daxor (NASDAQ: DXR) سيشارك في MedAxiom Cardiovascular Transforum Fall'25 في JW Marriott Austin من 16–18 أكتوبر 2025. تخطط الشركة لعرض نظام BVA diagnostics من الجيل التالي وبيان كيف تعالج التقنية حالات إعادة الدخول إلى المستشفيات وتحسين الموارد لمقدمي خدمات أمراض القلب والأوعية الدموية. قال المدير التنفيذي مايكل فيلدشوه إن الإطلاق من المتوقع أن يسرّع الزخم البيعي ويوسّع الاعتماد التجاري من خلال التواصل مع مبتكري أمراض القلب.
الظهور يضع Daxor في موقع يسمح بعرض الفوائد السريرية والتشغيلية للأنظمة الصحية والعملاء المحتملين الحاضرين المؤتمر في أُوستن، تكساس.
Daxor (NASDAQ: DXR) 将在 JW Marriott Austin 的 MedAxiom Cardiovascular Transforum Fall'25 展示，时间为 2025年10月16日至18日。公司计划首次推出其下一代 BVA 诊断系统，并演示该技术如何解决医院再入院问题和为心血管提供者实现资源优化。CEO Michael Feldschuh 表示，此次发布预计将加速销售势头并通过与心血管领域的创新者建立联系，推动更广泛的商业采用。
此次亮相将使 Daxor 有机会向在奥斯汀（TX）参加会议的卫生系统和潜在客户展示临床和运营上的好处。
- None.
- None.
OAK RIDGE, Tenn., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the MedAxiom Cardiovascular (CV) Transforum Fall’25 Conference being held at the JW Marriott Austin, from Thursday, October 16 - Saturday, October 18 in Austin, TX. The CV Transforum is the leading conference for cardiovascular organizational performance solutions, uniting industry innovators and thought leaders from across the country.
“We are thrilled to debut our eagerly awaited next generation BVA diagnostic system at this pivotal gathering,” said Michael Feldschuh, Daxor's CEO and President. “This launch is the catalyst we believe will accelerate our sales momentum and expand our market leadership. By connecting with top cardiovascular innovators, we will demonstrate how this breakthrough technology directly tackles key challenges: hospital readmissions and resource optimization. MedAxiom is the ideal platform to highlight our path to widespread commercial adoption.”
About Daxor Corporation
Daxor Corporation (NASDAQ: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor is proud to manufacture and distribute its patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic which offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion.
For more information, please visit our website at Daxor.com.
Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
COO – Head of Capital Markets
COREIR
(561)-479-8566-Cell
brets@coreir.com|www.coreir.com
FAQ
When and where will Daxor (DXR) exhibit at MedAxiom CV Transforum Fall'25?
What will Daxor (DXR) debut at the MedAxiom CV Transforum Fall'25?
How does Daxor say the new BVA system helps hospitals and clinicians?
Who commented on Daxor's product launch at MedAxiom and what did they say?
Is the MedAxiom CV Transforum Fall'25 focused on cardiovascular organizational performance?
